Association of MG53 with presence of type 2 diabetes mellitus, glycemic control, and diabetic complications

Abstract

Objectives Mitsugumin 53 (MG53) is a myokine that acts as a membrane repair protein in tissues. Data on the effect of MG53 on insulin signaling and type 2 diabetes mellitus (T2 DM) are still unknown; most are from preclinical studies. Nevertheless, some researchers have argued that it may be a new pathogenic factor, and therapies targeting MG53 may be a new avenue for T2 DM. Our study aims to evaluate the relationship of circulating MG53 levels with the presence of diabetes, diabetic complications, and glycemic control. Methods We conducted a case-control study with 107 patients with T2 DM and 105 subjects without insulin resistance-related disease. Concurrent blood samples were used for serum MG53 levels and other biochemical laboratory data. MG53 concentration was measured using Human-MG53, an enzyme-linked immunosorbent assay kit (Cat# CSB-EL024511HU). Results We found no difference in MG53 levels between the diabetic and control groups (p = 0.914). Furthermore, when the subjects were divided into tertiles according to their MG53 levels, we did not find any difference between the groups in terms of the presence of diabetes (p = 0.981). Additionally, no correlation was observed between weight, BMI, waist circumference, systolic and diastolic blood pressure, fasting blood glucose, HbA1c, albumin excretion in the urine, e-GFR levels, and MG53. Finally, MG53 levels were similar between the groups with and without microvascular and macrovascular complications of diabetes. Conclusion Our research finding provides insightful clinical evidence of lack of association between the levels of MG53 and T2 DM or glycemic control, at least in the studied population of Turkeys ethnicity. However, further clinical studies are warranted to establish solid evidence of the link between MG53, insulin resistance and glycemic control in a wider population elsewhere in the world.

MG53/TRIM72: multi-organ repair protein and beyond

“…In addition, a study showed that MG53 is not a key regulatory factor in the insulin signaling pathway in skeletal muscle through vitro and in vivo experiments (Philouze et al, 2021). A case-control study of 107 patients with type T2 diabetes and 105 subjects without insulin resistance-related diseases found a lack of association between the levels of MG53 and T2 diabetes (Andaç et al, 2023). Another clinical study found that MG53 could not mark cardiovascular risk and allcause mortality in patients with type 2 diabetes (Bianchi et al, 2023).…”